HomeCompareALPMY vs VICI

ALPMY vs VICI: Dividend Comparison 2026

ALPMY yields 3.04% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALPMY wins by $21.84M in total portfolio value· pulled ahead in Year 4
10 years
ALPMY
ALPMY
● Live price
3.04%
Share price
$16.75
Annual div
$0.51
5Y div CAGR
83.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.81M
Annual income
$19,791,199.83
Full ALPMY calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — ALPMY vs VICI

📍 ALPMY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALPMYVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALPMY + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALPMY pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALPMY
Annual income on $10K today (after 15% tax)
$258.78/yr
After 10yr DRIP, annual income (after tax)
$16,822,519.86/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, ALPMY beats the other by $16,306,250.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALPMY + VICI for your $10,000?

ALPMY: 50%VICI: 50%
100% VICI50/50100% ALPMY
Portfolio after 10yr
$11.89M
Annual income
$10,199,287.97/yr
Blended yield
85.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

ALPMY
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
2.8
Piotroski
7/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALPMY buys
0
VICI buys
0
No recent congressional trades found for ALPMY or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALPMYVICI
Forward yield3.04%6.52%
Annual dividend / share$0.51$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR83.1%44.3%
Portfolio after 10y$22.81M$966.2K
Annual income after 10y$19,791,199.83$607,376.13
Total dividends collected$22.54M$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ALPMY vs VICI ($10,000, DRIP)

YearALPMY PortfolioALPMY Income/yrVICI PortfolioVICI Income/yrGap
1$11,257$557.43$11,361$941.49$104.00VICI
2$13,119$1,073.83$13,320$1,481.32$201.00VICI
3$16,179$2,141.47$16,284$2,405.01$105.00VICI
4← crossover$21,831$4,519.18$21,040$4,071.78+$791.00ALPMY
5$33,794$10,434.70$29,209$7,285.49+$4.6KALPMY
6$63,800$27,640.77$44,443$14,006.51+$19.4KALPMY
7$157,564$89,297.64$75,822$29,512.55+$81.7KALPMY
8$545,974$377,380.84$148,733$69,726.75+$397.2KALPMY
9$2,821,884$2,237,691.96$344,394$189,413.75+$2.48MALPMY
10$22,810,616$19,791,199.83$966,234$607,376.13+$21.84MALPMY

ALPMY vs VICI: Complete Analysis 2026

ALPMYStock

Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Full ALPMY Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this ALPMY vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALPMY vs SCHDALPMY vs JEPIALPMY vs OALPMY vs KOALPMY vs MAINALPMY vs NNNALPMY vs EPRTALPMY vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.